Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
OME	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS:	O
The	O
patient	O
is	O
a	O
___	O
male	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
admitted	O
today	O
to	O
begin	O
cycle	O
1	O
week	O
1	O
high-dose	O
IL-2	O
therapy.	O
His	O
oncologic	O
history	O
began	O
when	O
he	O
presented	O
with	O
anemia	O
and	O
right	O
lower	O
quadrant	O
pain	O
in	O
___.	O
CT	O
scan	O
revealed	O
a	O
left	O
kidney	O
mass	O
and	O
lung	O
nodules.	O
Preoperatively,	O
he	O
signed	O
consent	O
for	O
the	O
dendritic	O
cell	O
vaccine	O
protocol	O
and	O
underwent	O
left	O
radical	O
laparoscopic	O
nephrectomy	O
by	O
Dr.	O
___	O
on	O
___.	O
Pathology	O
revealed	O
a	O
7.1-cm	O
tumor,	O
clear	O
cell	O
histology,	O
firm	O
and	O
grade	O
3	O
with	O
extension	O
into	O
perinephric	O
tissues	O
and	O
veins.	O
The	O
adrenal	O
gland	O
was	O
positive.	O
He	O
received	O
the	O
first	O
dendritic	O
cell	O
vaccine	O
on	O
___,	O
the	O
second	O
vaccine	O
on	O
___.	O
Torso	O
CT	O
on	O
___,	O
showed	O
disease	O
progression	O
in	O
the	O
lung.	O
High-dose	O
IL-2	O
therapy	O
was	O
recommended	O
and	O
he	O
began	O
eligibility	O
testing	O
with	O
a	O
head	O
CT	O
on	O
___	O
revealing	O
a	O
probable	O
left	O
temporal	O
lobe	O
lesion.	O
He	O
underwent	O
a	O
brain	O
MRI	O
of	O
neuro-oncology	O
follow-up	O
on	O
___	O
confirming	O
CNS	O
metastasis.	O
On	O
___	O
he	O
had	O
Cyberknife	O
to	O
that	O
lesion.	O
Follow-up	O
brain	O
MRI	O
1	O
month	O
later	O
revealed	O
stability	O
of	O
the	O
lesion,	O
but	O
mild	O
increased	O
cerebral	O
edema	O
without	O
mass	O
effect.	O
This	O
was	O
attributed	O
to	O
undergoing	O
the	O
procedure	O
without	O
steroids	O
in	O
order	O
to	O
start	O
IL-2	O
on	O
a	O
timely	O
fashion.	O
He	O
had	O
no	O
neurologic	O
symptoms	O
and	O
was	O
clear	O
to	O
begin	O
IL-2	O
and	O
presents	O
today	O
for	O
therapy.	O
PAST	O
MEDICAL	O
HISTORY:	O
History	O
of	O
a	O
bleeding	O
ulcer	O
in	O
___,	O
hypertension,	O
hyperlipidemia,	O
GERD,	O
diverticulosis,	O
history	O
of	O
migraines,	O
___	O
esophagus,	O
anemia	O
related	O
to	O
folate	O
deficiency,	O
status	O
post	O
appendectomy	O
in	O
___,	O
status	O
post	O
hemorrhoidectomy	O
in	O
___,	O
status	O
post	O
back	O
surgery	O
in	O
___,	O
rectal	O
prolapse	O
repair	O
in	O
___,	O
status	O
post	O
mastectomy	O
x2.	O
ALLERGIES:	O
Penicillin.	O
MEDICATIONS:	O
Lipitor	O
20	O
mg	O
p.o.	O
daily,	O
diltiazem	O
240	O
mg	O
p.o.	O
b.i.d.	O
on	O
hold,	O
folate	O
1	O
mg	O
daily,	O
Protonix	O
40	O
mg	O
daily,	O
triamterene/hydrochlorothiazide	O
75/50	O
one	O
tablet	O
daily,	O
valsartan	O
320	O
mg	O
p.o.	O
daily	O
on	O
hold,	O
vitamin	O
C	O
1000	O
mg	O
p.o.	O
daily,	O
Citrucel	O
1000	O
mg	O
p.o.	O
b.i.d.,	O
vitamin	O
B12	O
1000	O
mg	O
subcu	O
monthly.	O
PHYSICAL	O
EXAMINATION:	O
GENERAL:	O
Well-appearing	O
male	O
in	O
no	O
acute	O
distress.	O
Performance	O
status	O
zero.	O
VITAL	O
SIGNS:	O
97.8,	O
56,	O
18,	O
138/81,	O
O2	O
sat	O
96%	O
on	O
room	O
air.	O
HEENT:	O
Normocephalic,	O
atraumatic.	O
Sclerae	O
anicteric.	O
Moist	O
oral	O
mucosa	O
without	O
lesions.	O
NECK:	O
Supple.	O
No	O
JVD.	O
LYMPH	O
NODES:	O
No	O
cervical,	O
supraclavicular	O
or	O
bilateral	O
axillary	O
lymphadenopathy.	O
HEART:	O
Regular	O
rate	O
and	O
rhythm,	O
S1/S2.	O
CHEST:	O
Clear	O
bilaterally.	O
ABDOMEN:	O
Soft,	O
round,	O
nontender,	O
no	O
HSM	O
or	O
masses.	O
EXTREMITIES:	O
No	O
lower	O
extremity	O
edema.	O
SKIN:	O
Intact.	O
NEUROLOGIC	O
EXAM:	O
Alert,	O
oriented	B-Delirium
x3.	O
Speech	O
clear	O
and	O
fluent.	O
Strength	O
___	O
bilateral	O
upper	O
and	O
lower	O
extremities.	O
ADMISSION	O
LABS:	O
WBC	O
5.1,	O
hemoglobin	O
10.7,	O
hematocrit	O
31.1,	O
platelet	O
count	O
269,000,	O
INR	O
1.1,	O
BUN	O
32,	O
creatinine	O
1.7,	O
sodium	O
144,	O
potassium	O
3.4,	O
chloride	O
107,	O
CO2	O
27,	O
ALT	O
11,	O
AST	O
13,	O
CK	O
101,	O
total	O
bili	O
0.3,	O
albumin	O
4,	O
calcium	O
9.2,	O
phosphorus	O
3.0,	O
magnesium	O
2.2.	O
HOSPITAL	O
COURSE:	O
The	O
patient	O
was	O
admitted	O
and	O
underwent	O
central	O
line	O
placement	O
to	O
begin	O
therapy.	O
His	O
admission	O
weight	O
was	O
89.6	O
kg	O
and	O
he	O
received	O
interleukin-2	O
600,000	O
international	O
units	O
per	O
kilo	O
equaling	O
53.8	O
million	O
units	O
IV	O
every	O
8	O
hours	O
times	O
14	O
potential	O
doses.	O
During	O
this	O
week	O
he	O
received	O
12	O
of	O
14	O
doses	O
with	O
1	O
dose	O
held	O
related	O
to	O
acidosis	O
and	O
1	O
dose	O
held	O
related	O
to	O
shock.	O
On	O
treatment	O
day	O
#5	O
he	O
developed	O
shock	O
related	O
to	O
capillary	O
leak	O
syndrome	O
from	O
IL-2	O
therapy	O
requiring	O
initiation	O
of	O
dopamine	O
vasopressor	O
therapy.	O
Maximum	O
dopamine	O
was	O
5.5	O
mcg	O
per	O
kilogram	O
per	O
minute.	O
Continuous	O
blood	O
pressure	O
bedside	O
and	O
central	O
telemetry	O
monitoring	O
were	O
instituted.	O
Shortly	O
after	O
being	O
placed	O
on	O
dopamine,	O
he	O
developed	O
atrial	O
fibrillation	O
with	O
rhythm	O
between	O
130	O
and	O
140.	O
He	O
was	O
changed	O
to	O
Neo-Synephrine	O
with	O
spontaneous	O
conversion	O
back	O
to	O
normal	O
sinus	O
rhythm.	O
Digoxin	O
was	O
considered,	O
but	O
was	O
not	O
initiated	O
due	O
to	O
reconversion	O
to	O
sinus	O
rhythm.	O
He	O
was	O
maintained	O
on	O
telemetry	O
with	O
frequent	O
PAC	O
and	O
PVCs,	O
but	O
no	O
recurrent	O
atrial	O
fibrillation.	O
Further	O
IL-2	O
therapy	O
was	O
held	O
due	O
to	O
shock	O
and	O
atrial	O
fibrillation.	O
He	O
was	O
weaned	O
from	O
vasopressors	O
over	O
5	O
to	O
6	O
hour	O
period	O
without	O
recurrent	O
hypotension	O
noted.	O
Other	O
side	O
effects	O
during	O
this	O
week	O
included	O
rigors	O
improved	O
with	O
Demerol;	O
nausea	O
and	O
vomiting	O
improved	O
with	O
antiemetic	O
therapy;	O
diarrhea	O
improved	O
with	O
antidiarrheals,	O
mucositis;	O
development	O
of	O
an	O
erythematous	O
pruritic	O
skin	O
rash	O
and	O
fatigue.	O
During	O
this	O
week	O
he	O
developed	O
acute	O
renal	O
failure	O
with	O
a	O
peak	O
creatinine	O
of	O
3.5	O
with	O
associated	O
oliguria.	O
Metabolic	O
acidosis	O
was	O
noted	O
with	O
a	O
minimum	O
bicarb	O
of	O
17	O
improved	O
with	O
bicarbonate	O
replacement	O
intravenously.	O
Electrolytes	O
were	O
monitored	O
and	O
repleted	O
per	O
protocol.	O
Strict	O
I's	O
and	O
O's	O
and	O
serum	O
chemistries	O
were	O
maintained.	O
IV	O
fluids	O
were	O
continued	O
given	O
acute	O
renal	O
failure.	O
He	O
had	O
no	O
transaminitis,	O
but	O
developed	O
hyperbilirubinemia	O
with	O
a	O
peak	O
bilirubin	O
of	O
2.2.	O
He	O
was	O
anemic	O
without	O
need	O
for	O
packed	O
red	O
blood	O
cell	O
transfusion.	O
He	O
had	O
no	O
coagulopathy	O
or	O
myocarditis	O
noted.	O
He	O
developed	O
thrombocytopenia	O
with	O
a	O
platelet	O
count	O
low	O
of	O
60,000	O
without	O
evidence	O
of	O
bleeding.	O
By	O
___,	O
he	O
had	O
recovered	O
from	O
side	O
effects	O
to	O
allow	O
for	O
discharge	O
to	O
home.	O
CONDITION	O
ON	O
DISCHARGE:	O
Stable.	O
Alert	O
and	O
ambulatory.	O
DISCHARGE	O
STATUS:	O
To	O
home	O
with	O
his	O
wife.	B-Lives_alone
DISCHARGE	O
DIAGNOSES:	O
___	O
renal	O
cell	O
carcinoma,	O
status	O
post	O
cycle	O
1,	O
week	O
1,	O
high-dose	O
IL-2	O
therapy	O
complicated	O
by	O
shock,	O
acute	O
renal	O
failure	O
and	O
atrial	O
fibrillation.	O
DISCHARGE	O
MEDICATIONS:	O
Lasix	O
20	O
mg	O
p.o.	O
daily	O
x5	O
days	O
or	O
until	O
you	O
reach	O
pretreatment	O
weight,	O
Tylenol	O
___	O
tablets	O
q.i.d.	O
p.r.n.	O
fever	O
or	O
pain,	O
lorazepam	O
0.5	O
to	O
1	O
mg	O
3	O
times	O
a	O
day	O
as	O
needed	O
for	O
nausea/vomiting,	O
insomnia	O
or	O
anxiety,	O
Benadryl	O
___	O
mg	O
q.i.d.	O
p.r.n.	O
pruritus,	O
Compazine	O
10	O
mg	O
q.i.d.	O
p.r.n.	O
nausea/vomiting,	O
Cipro	O
250	O
mg	O
p.o.	O
b.i.d.	O
x5	O
days,	O
Lomotil	O
___	O
tablets	O
q.i.d.	O
p.r.n.	O
loose	O
stools,	O
Eucerin	O
cream	O
topically,	O
Sarna	O
lotion	O
topically,	O
Protonix	O
40	O
mg	O
p.o.	O
daily,	O
Nystatin	O
5	O
mL	O
p.o.	O
q.i.d.	O
p.r.n.	O
thrush.	O
Gelclair	O
15	O
mL	O
t.i.d.	O
p.r.n.	O
mucositis.	O
FOLLOW-UP	O
PLANS:	O
The	O
patient	O
will	O
return	O
in	O
1	O
week	O
for	O
week	O
#2	O
of	O
therapy.	O
___	O
___	O
Dictated	O
By:	O
___,	O
NP	O
MEDQUIST36	O
D:	O
___	O
14:41:26	O
T:	O
___	O
16:56:13	O
___:	O
___	O
cc:	O
___	O

